Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Ability to give informed consent and comply with study procedures.~* Participant able/willing to hold off receiving prophylactic immunizations (like influenza or pneumococcal vaccines) during the study period.~Exclusion Criteria:~* Use of corticosteroids within 2 weeks prior to screening visit.~* First degree relative (parent, sibling or child) with history of autoimmune disease.~* Presence of chronic medical illness including but not limited to chronic kidney-, liver-, cardio-vascular diseases, immunodeficiencies, anemia, B12 deficiency, malignancies, or chronic active infections.~* History of acute gastrointestinal illness within 2 weeks prior to oral KLH administration.~* For women of child bearing age, participant unwilling to defer pregnancy, has a positive urine pregnancy test or is currently pregnant or lactating.~* Use of an investigational drug within 3 months of the screening visit.~* History of acute febrile illness within 1 week of screening visit.~* History of allergy to shellfish, previous exposure to KLH/product containing KLH or known-sensitivity to KLH / components of KLH preparation.~* Participants receiving any immunizations within 1 month prior to screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Immucothel alone (Part A) (Type: EXPERIMENTAL): 100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
- Immucothel+Montanide (Part A) (Type: EXPERIMENTAL): If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
- Immucothel alone or Immucothel+Montanide (Part B) (Type: EXPERIMENTAL): Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35.

Based on this trial design, predict the completion outcome and termination type (if applicable).